NCT01254019

A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 186 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: 5 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.

Conditions

• Muscular Dystrophies

Interventions

Type	Name	Description
DRUG	GSK2402968 6mg/kg/week	subcutaneous

Timeline

• Start date: 2010-12-02
• Primary completion: 2013-06-28
• Completion: 2013-06-28
• First posted: 2010-12-06
• Last updated: 2019-01-28
• Results posted: 2019-01-28

Locations

47 sites across 20 countries: Argentina, Belgium, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye)